Pepe et al. [38] enrolled 40 men with low-risk prostate cancer who had already been on active surveillance for 48–60 months to undergo PSMA PET and mpMRI prior to a scheduled repeat biopsy. This evidence concerns the gene FOLH1 and prostate cancer.